Clinical Trial Update: Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating saroglitazar 4 mg in liver transplant recipients with nonalcoholic fatty liver disease (NAFLD) to assess safety, tolerability, and effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• Saroglitazar (saroglitazar)

Snippet

Sponsor: Zydus Therapeutics Inc. | Conditions: Liver Transplant; Complications, NAFLD | Phase 2 | Status: COMPLETED | Results posted: 2024-10-24